Vectra DA for the objective measurement of disease activity in patients with rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 32, Issue , 2014, Pages S29-S34

  Segurado, Oscar G ^a   Sasso, Eric H ^a  

^a Crescendo Bioscience   (United States)

Author keywords

Multi biomarker disease activity (MBDA) score; Rheumatoid arthritis; Therapy response monitoring; Tight control; Vectra DA

Indexed keywords

C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLYCOPROTEIN GP 39; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LEPTIN; METHOTREXATE; PREDNISONE; RESISTIN; STROMELYSIN; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN A; ANTIRHEUMATIC AGENT; AUTACOID; BIOLOGICAL MARKER;

ACCURACY; ARTICLE; BLOOD ANALYSIS; CLINICAL DECISION MAKING; DIAGNOSTIC KIT; DISEASE ACTIVITY; DISEASE COURSE; FIBROMYALGIA; HUMAN; JOINT RADIOGRAPHY; OSTEITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPRODUCIBILITY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SEROLOGY; SYNOVITIS; TREATMENT RESPONSE; VALIDATION STUDY; ARTHRITIS, RHEUMATOID; BIOMECHANICS; BLOOD; DRUG MONITORING; IMMUNOASSAY; IMMUNOLOGY; JOINT; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BIOMECHANICAL PHENOMENA; DRUG MONITORING; HUMANS; IMMUNOASSAY; INFLAMMATION MEDIATORS; JOINTS; METHOTREXATE; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84922395196     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. SMOLEN JS, ALETAHA D, BIJLSMA JW et al.: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 631-7.
2. PINCUS T, SEGURADO OG: Most visits of most patients with rheumatoid arthritis to most rheumatologists do not include a formal quantitative joint count. Ann Rheum Dis 2006; 65: 820-2.
3. ANDERSON J, CAPLAN L, YAZDANY J et al.: Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 2012; 64: 640-7.
4. PINCUS T, YAZICI Y, BERGMAN M, SWEARINGEN C, HARRINGTON T: A proposed approach to recognise "near-remission" quantitatively without formal joint counts or laboratory tests: a patient self-report questionnaire routine assessment of patient index data (RAPID) score as a guide to a "continuous quality improvements". Clin Exp Rheumatol 2006; 24(6 Suppl. 43): S60-5; quiz S66-73.
5. KHAN NA, SPENCER HJ, ABDA E et al.: Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) 2012; 64: 206-14.
6. MASRI KR, SHAVER TS, SHAHOURI SH et al.: Validity and reliability problems with patient global as a component of the ACR remission criteria as used in clinical practice. J Rheumatol 2012; 39: 1139-45.
7. SOKKA T, PINCUS T: Joint counts to assess rheumatoid arthritis for clinical research and usual clinical care: advantages and limitations. Rheum Dis Clin North Am 2009; 35: 713-22.
8. O'CONNELL JX: Pathology of the synovium. Am J Clin Pathol 2000; 114: 773-84.
9. KEEN HI, WAKEFIELD RJ, GRAINGER AJ, HENSOR EM, EMERY P, CONAGHAN PG: An ultrasonographic study of osteoarthritis of the hand: synovitis and its relationship to structural pathology and symptoms. Arthritis Rheum 2008; 59: 1756-63.
10. SOKKA T, PINCUS T: Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol 2009; 36: 1387-90.
11. WOLFE F: The many myths of erythrocyte sedimentation rate and C-reactive protein [editorial]. J Rheumatol 2009; 36: 1568-9.
12. KAY J, MORGACHEVA O, MESSING SP et al.: Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther 2014; 16: R40.
13. SMOLEN JS, ALETAHA D: Patients with rheumatoid arthritis in clinical care. Ann Rheum Dis 2004; 63: 221-25.
14. ALETAHA D, FUNOVITS J, BREEDVELD FC et al.: Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum 2009; 60: 1242-9.
15. EMERY P, van der HEIJDE D, OSTERGAARD M et al.: Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 2126-30.
16. McINNES IB, SCHETT G: The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-19.
17. BROWN AK CONAGHAN PG, KARIM Z et al.: An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008; 58: 2958-67.
18. CENTOLA M, CAVET G, SHEN Y et al.: Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS ONE 2013; 8: e60635.
19. EASTMAN PS, MANNING WC, QURESHI F et al.: Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. J Pharm Biomed Anal 2012; 70: 415-24.
20. CURTIS JR, van der HELM-van MIL AH, KNEVEL R et al.: Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res 2012; 64: 1794-803.
21. BAKKER MF, CAVET G, JACOBS JW et al.: Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis 2012; 71: 1692-7.
22. HIRATA S, DIRVEN L, SHEN Y et al.: A multibiomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology (Oxford) 2013; 52: 1202-7.
23. LI W, SASSO EH, EMERLING D et al.: Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use. Curr Med Res Opin 2013; 29: 85-92.
24. HANEY DJ, CAVET G, DUREZ P et al.: Correlation of a multi-biomarker disease activity response assessment to disease activity score 28 (C-reactive protein) response assessment and Omeract Ramris scores in a placebo-controlled rheumatoid arthritis clinical trial with abatacept (ASSET). Arthritis Rheum 2012; 64 (Suppl. 10): S913.
25. KRABBE S, BOLCE R, BRAHE C et al.: Validation of a multi-biomarker disease activity score in rheumatoid arthritis in relation to imaging inflammation and damage. Ann Rheum Dis 2014; 73: (Suppl. 2): 396.
26. MA M, GARROOD T, LI W et al.: multi-biomarker disease activity (Vectra® DA Algorithm) score is associated with power Doppler ultrasound in patients with rheumatoid arthritis in low disease activity state: the REMIRA Cohort. Ann Rheum Dis 2014; 73: (Suppl. 2): 606.
27. van der HELM-van MIL A, KNEVEL R, CAVET G et al.: An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. Rheumatology (Oxford) 2013; 52: 839-46.
28. BRUYNESTEYN K, van der HEIJDE D, BOERS M et al.: Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum 2002; 46: 913-20.
29. HAMBARDZUMYAN K, BOLCE R, SAEVARSDOTTIR S et al.: Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial (published online before print 8 May 2014). Ann Rheum Dis doi:10.1136/ annrheumdis-2013-204986.
30. HAMBARDZUMYAN K, BOLCE R, SAEVARSDOTTIR S et al.: In early RA patients the multi-biomarker disease activity score at different time-points is predictive of subsequent radiographic progression. Ann Rheum Dis 2014; 73 (Suppl. 2): 382-3
31. MARKUSSE I, DIRVEN L, van den BROEK M et al.: A multi-biomarker disease activity score for rheumatoid arthritis predicts radiographic joint damage in the BeSt study. J Rheumatology 2014 Aug 15. pii: jrheum.131412.
32. HIRATA S, LI W, DEFRANOUX N et al.: Repeated high or low multi-biomarker disease activity (Vectra® DA algorithm) scores associated with radiographic outcomes in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. Arthritis Rheum 2013; 65 (Suppl. 10): S616-7.
33. TOMS J, SOUKUP T, BRADNA P et al.: Disease activity composite indices in patients with rheumatoid arthritis and concomitant fibromyalgia. J Rheumatol 2010, 37: 468.
34. LEE Y, HANEY D, ALEXANDER C et al.: Application of a multi-biomarker disease activity (Vectra® DA) score for assessing rheumatoid arthritis patients with low CRP or fibromyalgia. Ann Rheum Dis 2013; 72 (Suppl. 3): A612-3.
35. JURGENS M, BIJLSMA J, JACOBS J: Response to methotrexate plus prednisone in CAMERA II using a multi-biomarker disease activity test (Vectra DA) and DAS28-ESR. Ann Rheum Dis 2013; 72 (Suppl. 3): A395-6.
36. HIRATA S, LI W, DEFRANOUX N et al.: A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study. Mod Rheumatol 2014 Oct 8:1-6. [Epub ahead of print].
37. BURMESTER G, WEINBLATT M, McINNES I et al.: Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis 2013; 72: 1445-52.
38. YAMAOKA K, KUBO S, LI W et al.: Effects of tofacitinib treatment on leptin and other components of the multi-biomarker disease activity score in patients with rheumatoid arthritis. Ann Rheum Dis 2014;73 (Suppl. 2): 507-8.
39. Biomarkers of anti-TNF-α therapy efficacy in rheumatoid arthritis to define unresponsive patients (BATTER-UP) NCT01211678 [date cited 15 July 2014]. http://clinicaltrials. gov/show/NCT01211678.